QL Biopharm Completes Dosing of First Patient in HORIZON-1, a Phase 3 Trial for Weight Loss with Zovaglutide, a Once-Monthly GLP-1 RA Peptide BEIJING, China, January 19, 2026 On January 16, 2026, Beijing QL Biopharmaceutical Co, Ltd (QL Biopharm) dosed the first patient in its Phase 3 clinical trial, HORIZON-1, which will evaluate QL Biopharms ultra-long-acting GLP-1 receptor agonist (GLP-1 RA), zovaglutide (ZT002)
However, there are several other FDA-approved medications that offer similar benefits
This surge is forcing employers to reassess their benefit strategies, balancing the desire to offer comprehensive coverage with the need to manage budgets
Curb stress-eating: Life throws curveballs, and GLP-1 helps you recognize real hunger versus emotional or stress-driven cravings